

# Phospho-Jak1 (Tyr1034/1035) (F11) rabbit mAb

[www.abwizbio.com](http://www.abwizbio.com)

Support: [info@abwizbio.com](mailto:info@abwizbio.com)

Order: [sales@abwizbio.com](mailto:sales@abwizbio.com)


**Catalog:** #2411

**Store at:** -20°C


*For Research Use Only. Not For Use In Diagnostic Procedures.*

Applications	Detection	Clonality	Isotype
Flow Cytometry	Anti-Rabbit IgG	Monoclonal	Rabbit IgGk

<b>Format:</b>	Unconjugated
<b>Cross Reactivity:</b>	Predicted to work with mouse, rat and other homologues.
<b>Formulation:</b>	1X PBS, 0.02% NaN <sub>3</sub> , 50% Glycerol, 0.1% BSA
<b>Preparation:</b>	Protein A+G
<b>Reactivity:</b>	Human, Mouse
<b>Recommended Usage:</b>	1µg/mL – 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.
<b>Immunogen:</b>	A synthetic phospho-peptide corresponding to residues surrounding Tyr1034/1035 of human phospho-Jak1
<b>Description:</b>	Jak1 plays an essential role in the IFN-α and IFN-γ response pathways and is tyrosine-phosphorylated upon cellular exposure to these signals. Jak1 oral inhibitors have been used to benefit patients with advanced myelofibrosis, where Jak1 was initially shown to be constitutively active in the peripheral blood cells of these patients. Targeted, small-molecule Jak inhibitors have also been used for treatment of rheumatoid arthritis. In cases of advanced melanoma, acquired resistance to PD-1 blockade drugs is associated with loss-of-functions of mutations in Jak1/2 genes. These mutations block interferon gamma signaling and prevent programmed death ligand 1 (PD-L1) expression in tumor cells.
<b>References:</b>	Muller M, Briscoe J, Laxton C et al. (1993) Nature. 366: 129-135. Verstovesk S, Kantarjian H, Mesa RA et al. (2010) New England Journal of Medicine. 363: 1117-1127. Shin DS, Zaretsky JM, Escuin-Ordinas H et al. (2017) Cancer Discovery. 7:188-201. Boyle DL, Soma K, Hodge J, et al. (2014) Annals of the Rheumatic Diseases. 74: 1311-1316.



Flow cytometric analysis of Jurkat cells untreated (red) or treated with IFN $\alpha$  + IL-4 + pervanadate (green) using Phospho-Jak1 (Tyr1034/1035) antibody Jak1Y10341035-F11 at 0.01 $\mu$ g/mL. Cat. #2411, or concentration matched isotope control, Cat# 2141 for untreated (gray ) or treated with IFN $\alpha$ +IL4+Pervanadate (blue) .



	IgG	Treatment	Peptide Block	Median : BL1-A
	F11	IFN $\alpha$ IL4Pv	Non-Phos.	929
	F11	Ctrl	Non-Phos.	268
	F11	IFN $\alpha$ IL4Pv	Phospho.	347
	F11	Ctrl	Phospho.	268
	F11	IFN $\alpha$ IL4Pv	-	921
	F11	Ctrl	-	268
	2' only	Ctrl	-	268

Peptide blocking flow cytometric analysis of Jurkat cells secondary antibody only negative control (light blue) or untreated (red) or treated with IFN $\alpha$  + IL-4 + pervanadate (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (purple) using Phospho-Jak1 (Tyr1022/1023) antibody Jak1Y10221023-F11 at 0.001 $\mu$ g/mL. Cat. #2411.